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 The CRASH3 results are out, but do we know what to do? The study enrolled 9202 head 
injured patients within 3 hours of injury with a Glasgow Coma Scale (GCS) of 12 or less, or 
any intracranial bleeding on CT scan and randomised them to Tranexamic Acid (TXA) or 
placebo.  The relative risk (RR) of all-cause mortality (RR 0.96, 95% CI 0.89-1.04) and head 
injury death (RR 0.94, 95% CI 086-1.02) among those receiving TXA were not significant. 
However there were significant differences in subgroups who were less severely injured (RR 
0.89 95%CI 0.80-1.00 if those with GCS=3 or bilateral fixed pupils were excluded, and RR 
0.78, 95% CI 0.64 to 0.95, in the GCS 9 to 15 subgroup) or treated earlier (p=0.005 for time 
effect)[1]. 
 
The results need to be considered in the context of earlier CRASH2[2] results, which showed 
a reduction in all-cause mortality (RR 0.91, 0.85 to 0.97) and death due to bleeding (RR 0.85, 
0.76-0.96) if trauma patients who were bleeding or at risk of bleeding were given TXA. In 
both CRASH2 and CRASH3 the TXA was given in the emergency department. 
 
Interpretation 
Both the CRASH2 and CRASH3 studies are on the borderline for power to detect important 
differences, despite being among the largest ever conducted in trauma care. However, 
there are unlikely to be better powered studies ever undertaken, so the current information 
has to be the basis for clinical decision making. A rigid evidence-based medicine approach 
 ? ‘ƚŚŝƐǁĂƐĂŶĞŐĂƚŝǀĞƐƚƵĚǇ ? don't usĞdy ? ?ƌŝƐŬƐĂůŽƐƚŽƉƉŽƌƚƵŶŝƚǇƚŽŝŵƉƌŽǀĞĐĂƌĞ ?
,ŽǁĞǀĞƌ ?ƚŚĞŽƉƉŽƐŝƚĞǀŝĞǁ ? ‘dyŝƐŚĂƌŵůĞƐƐŐŝǀĞŝƚƚŽĂůůŚĞĂĚŝŶũƵƌŝĞƐ ? ?ĂůƐŽƌŝƐŬƐĂůŽƐƚ
opportunity to improve care. Looking at confidence intervals rather than just thinking about 
the result as significant / non-significant is helpful, but translation of the CRASH3 trial results 
into clinical practice will ultimately be a matter of clinical judgement, which will 
ƵŶĚŽƵďƚĞĚůǇůĞĂĚƚŽǀĂƌŝĂƚŝŽŶŝŶĐůŝŶŝĐĂůƉƌĂĐƚŝĐĞĂƐƚŚĞƌĞŝƐŶŽ ‘ƌŝŐŚƚ ?ĂŶƐǁĞƌ ? 
 
Setting of administration ʹ hospital or prehospital?. 
The first open question is about the setting of administration. None of the CRASH studies 
have given TXA in the prehospital phase, but across TXA studies there is a strong time effect, 
with earlier treatment linked to better outcomes[3]. The strong time effect was used as a 
justification for extrapolating from the CRASH2 results to recommend prehospital TXA 
treatment[4]. Prespecified analysis in CRASH3 showed a similar time effect, so it seems 
logical to assume that prehospital treatment would give better outcomes than delaying 
treatment until after a CT scan in the Emergency Department (although this has not been 
tested). 
 
Which patients should get prehospital treatment? 
As a prehospital GCS of 12 or less is associated with a 25% or more chance of having an 
abnormal CT scan,[5] it seems reasonable to recommend prehospital TXA treatment for 
these patients. This recommendation may be stronger in high income countries as post hoc 
analysis in the CRASH 3 paper suggested a greater reduction in head injury deaths with TXA 
(RR 0.76 for all severities) in high income countries. 
 
It is more difficult to make a recommendation for head injury patients with a prehospital 
GCS 13-15, as they are much less likely to have a bleed, so earlier treatment would mean 
unnecessarily giving TXA to much larger numbers of patients. There are three potential ways 
 of implementing the CRASH3 findings in patients with a prehospital GCS of 13 to 15 (Table 
1): 
 
1) No prehospital treatment  ? await ED CT scan result 
Treatment after CT (as per the CRASH3 trial method) would be expected to give the same 
effect as the trial. Unfortunately, the effect in the GCS 13-15 group is not reported 
separately in the CRASH3 paper. In a deviation from the statistical analysis plan[6], these 
patients were reported in a combined GCS 9  ? 15 group, with a 22% reduction in head injury 
death RR 0.·78 (0.64 ?0.95). 
 
2) Prehospital treatment ǁŝƚŚdyĂĐĐŽƌĚŝŶŐƚŽƚŚĞůŽĐĂů ‘,ĞĂĚ/ŶũƵƌǇdZƵůĞƐ ? 
Early identification of  intracerebral bleed is difficult[5], but minor head injury is routinely risk 
stratified ĂĐĐŽƌĚŝŶŐƚŽ ‘,ĞĂĚ/ŶũƵƌǇdZƵůĞƐ ? ?ĂĐŚŝĞǀing a positive CT rate of about 5% 
(between 2% and 8% depending on the population) but <1% for neurosurgical abnormality[7-
9]. There seems to be a logic (but no evidence) in thinking that if a patient with a minor head 
injury is at sufficient risk from intracranial bleeding to justify a CT scan (with associated 
radiation adverse effects) they also are at sufficient risk to warrant early TXA treatment. 
There would be simplicity in aligning the indications for TXA therapy with the local CT head 
scanning guidance. However, the CT head rules are often falsely positive (most minor head 
injury CTs are normal), so many patients would have unnecessary TXA treatment. 
 
3) Prehospital treatment using a new risk stratification tool 
The developers of the clinical decision rules for CT in minor head injury chose to maximise 
sensitivity (to detect all patients with traumatic brain injury) accepting low specificity. 
However, iƚǁŽƵůĚďĞƉŽƐƐŝďůĞƚŽƵƐĞƚŚĞƐĂŵĞŝŶĨŽƌŵĂƚŝŽŶƚŽĐƌĞĂƚĞĂ ‘ƌƵůĞ ?with increased 
specificity for intra-cranial haemorrhage (the trade-off being reduced sensitivity). A more 
specific rule would allow prehospital TXA therapy to be focussed to a higher risk group. 
Large prospective TBI studies supported by the International Initiative for Traumatic Brain 
Injury Research[10] suggest that blood based biomarkers of brain injury may improve the 
specificity of the head CT clinical decision rules, and  ? if developed as point of care tests  ? 
could potentially better target early (prehospital) TXA in patients with GCS 13 -15 head 
injury. 
 
What is the Number Needed to Treat (NNT) for each prehospital strategy? 
There is no NNT calculated in the CRASH3 paper, and separate relative risks were not 
provided for moderate and mild GCS scores (GCS 9 to 15 was considered as one group). This 
is unfortunate as the strong relationship between the incidence of intra-cranial haematoma 
and GCS means that the NNT is crucially dependent on the initial GCS. 
 
In the GCS 9-15 group in the CRASH3 study the Absolute Risk Reduction was 1.7%, so the 
NNT to prevent one head injury death in this group of patients (who all have an intra-cranial 
bleed) can be calculated as 59 (Table 2). If the CT head scan indications were used to move 
TXA treatment earlier (either prehospital or before CT scan in hospital) the estimated NNT is 
between 294 and 1111 (Table 2). If TXA treatment was given to all head injuries the NNT 
would be several thousands. These are imprecise estimates which assume that the 
treatment effect (Risk Ratio) is constant across the GCS 9 to 15 range, but these calculations 
do give an indication of NNT. 
  
As the NNT for a treatment increases, the key clinical decision is estimating where the 
accumulated harm (adverse effects) in patients who do not need the treatment outweighs 
the benefits. So, an estimation of the harm of TXA treatment is crucial. None of the 
prospective TXA trauma trials has shown an increase in venous thrombo-embolic or other 
complications (retrospective studies show an increase, but this is inevitable as only the most 
severely injured are treated with TXA). There is no drug without adverse effects, but the 
rate with TXA must be very low if it does not register in such large studies.[11]. However, if a 
NNT of thousands is being considered, even a very low adverse event rate might be 
significant. 
 
In current use of CT head scanning for minor head injury management there is a precedent 
for a NNT in the thousands. There is no controlled trial evidence that defines the effect of 
early CT scanning on mortality, but it is likely that thousands of CT scans need to be 
performed in the GCS 13  ? 15 group in order to prevent one death, as <1% of CT scans in 
this group have a neurosurgical abnormality[12] and most patients survive neurosurgery. CT 
scanning a large number of low risk patients is accepted emergency care practice, so we 
should not necessarily dismiss a TXA implementation that also involves treatment of a very 
large number of patients for each additional survivor. 
 
Children. 
There is unlikely ever to be a study similar to CRASH3 performed in children. As the 
coagulation system in children is very similar to the adult it is likely that, as with previous 
TXA trauma implementation, children will be treated with a weight adjusted dose using the 
same local guideline as adults. 
 
Conclusions. 
Decisions about the implementation of the CRASH3 results are complex, and it seems as if 
we should think about stratifying patients. The key implementation choices for the GCS <13 
group (who probably have a NNT in the hundreds) are whether to move treatment into the 
prehospital phase, and whether the patients with the most severe injuries should be 
treated. Overall, in high income settings it seems reasonable to suggest prehospital 
intravenous TXA should be given for all injured patients with a prehospital GCS of 12 or less. 
 
The situation for the GCS13-15 patients (who may have a NNT in the thousands) is more 
complex, particularly as the current CRASH3 publication does not give all the data needed to 
estimate a NNT for this group. The three approaches in GCS 13-15 patients are either; to 
only give TXA in the emergency department after a positive CT showing an intra-cranial 
bleed; or to give early (prehospital) treatment to all those at risk according to the local CT 
head scan criteria; or to develop a new method of prehospital risk stratification that 
emphasises specificity over sensitivity. In the GCS 13-15 group the current best 
recommendation seems to be to treat patients in the ED after a bleed is found on CT scan, 
but the future is likely to be the development of a clinical decision rule for TXA use with 
higher specificity for cerebral bleeding than the current CT scanning rules. 
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Table 1 
Options for Prehospital TXA implementation in suspected isolated TBI 
 
 
 
Implementation 
Strategy 
Prevalence 
of cerebral 
bleed 
Mortality Risk 
Ratio 
ARR Estimated 
NNT 
Notes 
TXA in ED after 
CT (CRASH3 
method) 
100% 19.5% 0.78 1.7% 59 ARR assumed to be 
the same as the GCS 
9-15 group in the 
CRASH3 paper. 
Prehospital TXA 
if CT indicated 
(estimated) 
2% to 8% 0.39% to 
1.56% 
0.78 0.09 to 
0.34% 
294 to 
1111 
This NNT will be 
smaller if early 
treatment is more 
effective 
Prehospital TXA 
ƚŽĂůů ?ŚĞĂĚ
ŝŶũƵƌĞĚ ?
(estimated) 
<1% <0.195 0.78 <0.04% > 2500 Prevalence of 
cerebral bleed may 
be lower depending 
ŽŶĚĞĨŝŶŝƚŝŽŶŽĨ ‘ŚĞĂĚ
ŝŶũƵƌĞĚ ? ? 
 
Table 2 
Impact of different implementation strategies on NNT in GCS 13-15 group 
Note: ARR = Mortality ʹ (Mortality * Risk Ratio) 
 
 
Prehospital GCS 3-12 
(>25% risk of intracranial injury) 
(i) No prehospital administration (pre alert ED). 
(ii) Give prehospital TXA to all. 
(iii) Give prehospital TXA, excluding patients with GCS =3 or bilateral fixed pupils. 
 
Prehospital GCS 13-15 
(<1% risk of intra-cranial injury: 2-8% risk if indication for CT) 
x No prehospital administration (pre alert ED to enable early CT). 
x Give prehospital TXA if there is an indication for CT. 
x Future high specificity rule (? including near patient blood biomarkers). 
